Patents by Inventor Adam Ross PATTERSON

Adam Ross PATTERSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of a MAGL inhibitor
    Patent number: 12152029
    Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: November 26, 2024
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Vetter, Martin Juhl, Heidi Lopez De Diego, Cheryl A. Grice, John J. M. Wiener, Daniel J. Buzard, Amy Allan, Susana Del Rio Gancedo, Samuel George Andrew, Antonio Cincotti, Adam Ross Patterson, Richard James Edwards
  • MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE
    Publication number: 20240199627
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one.
    Type: Application
    Filed: March 4, 2024
    Publication date: June 20, 2024
    Inventors: Suzanne BUTTAR, Mateusz PITAK, Adam Ross PATTERSON, Samuel Alexander STRATFORD, Ioana SOVAGO, Jun XU, Peng ZHOU, Haojuan WEI, Kuangchu DAI
  • Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
    Patent number: 12006319
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 11, 2024
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Suzanne Buttar, Mateusz Pitak, Adam Ross Patterson, Samuel Alexander Stratford, Ioana Sovago, Jun Xu, Peng Zhou, Haojuan Wei, Kuangchu Dai
  • CRYSTALLINE FORMS OF A MAGL INHIBITOR
    Publication number: 20230265095
    Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)b enzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 1, 2022
    Publication date: August 24, 2023
    Inventors: Thomas VETTER, Martin JUHL, HEIDI LOPEZ DE DIEGO, Cheryl A. GRICE, John J.M. WIENER, Daniel J. BUZARD, Amy ALLAN, Susana DEL RIO GANCEDO, Samuel George ANDREW, Antonio CINCOTTI, Adam Ross PATTERSON, Richard James EDWARDS
  • PROCESSES FOR PREPARING TUCATINIB POLYMORPHS
    Publication number: 20230068593
    Abstract: The present invention is directed to processes for making various polymorphs of tucatinib, designated herein as Form I, Form II, and Form III of tucatinib. These forms can then be used to prepare pharmaceutical formations containing tucatinib. Tucatinib is a tyrosine kinase inhibitor that is indicated for the treatment of breast cancer.
    Type: Application
    Filed: July 27, 2022
    Publication date: March 2, 2023
    Inventors: Thierry BONNAUD, Adam Ross PATTERSON, Zoe PRENTICE, Mark Alexander WRIGHT
  • MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE
    Publication number: 20210107911
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
    Type: Application
    Filed: December 2, 2020
    Publication date: April 15, 2021
    Inventors: Suzanne BUTTAR, Mateusz PITAK, Adam Ross PATTERSON, Samuel Alexander STRATFORD, Ioana SOVAGO, Jun XU, Peng ZHOU, Haojuan WEI, Kuangchu DAI